Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 73 citing articles:

Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis
Caroline Stein, Hasan Nassereldine, Reed J D Sorensen, et al.
The Lancet (2023) Vol. 401, Iss. 10379, pp. 833-842
Open Access | Times Cited: 306
Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022
Fayette Klaassen, Melanie H. Chitwood, Ted Cohen, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 3, pp. 355-361
Open Access | Times Cited: 34
SARS-CoV-2 Reinfections in Health-Care Workers, 1 March 2020–31 January 2023
Luca Cegolon, Greta Camilla Magnano, Corrado Negro, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1551-1551
Open Access | Times Cited: 28
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history
Hermaleigh Townsley, Joshua Gahir, Timothy Russell, et al.
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0294897-e0294897
Open Access | Times Cited: 7
A mini review of reinfection with the SARS‐CoV‐2 Omicron variant
Hongwei Shen, Dingqiang Chen, Chenglin Li, et al.
Health Science Reports (2024) Vol. 7, Iss. 4
Open Access | Times Cited: 7
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states
Thomas Müller, Takuya Sekine, Darya Trubach, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 704
Open Access | Times Cited: 20
Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection
Wen Shi Lee, Hyon‐Xhi Tan, Arnold Reynaldi, et al.
Science Advances (2023) Vol. 9, Iss. 29
Open Access | Times Cited: 20
Pediatric Hospitalizations and ICU Admissions Due to COVID-19 and Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 in England
Joseph Ward, Rachel Harwood, Simon Kenny, et al.
JAMA Pediatrics (2023) Vol. 177, Iss. 9, pp. 947-947
Open Access | Times Cited: 20
Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation
Sivan Gazit, Yaki Saciuk, Galit Perez, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 7, pp. e495-e505
Open Access | Times Cited: 17
The Associated Factors of SARS-CoV-2 Reinfection by Omicron Variant — Guangdong Province, China, December 2022 to January 2023
C.S. Cai, Yihong Li, Ting Hu, et al.
China CDC Weekly (2023) Vol. 5, Iss. 18, pp. 391-396
Open Access | Times Cited: 16
The emerging pandemic recent: SARS-CoV-2
Yoojin Cha, Wondong Jung, Min Jae Seo, et al.
Life Cycle (2023) Vol. 3
Open Access | Times Cited: 15
Antibody and B Cell Responses to SARS-CoV-2 Infection and Vaccination: The End of the Beginning
Katharina Röltgen, Scott D. Boyd
Annual Review of Pathology Mechanisms of Disease (2023) Vol. 19, Iss. 1, pp. 69-97
Open Access | Times Cited: 15
Current state of COVID-19 in children: 4 years on
Annabel Powell, Alexander C. Dowell, Paul Moss, et al.
Journal of Infection (2024) Vol. 88, Iss. 5, pp. 106134-106134
Open Access | Times Cited: 6
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022
Charlotte Lanièce Delaunay, Iván Martínez‐Baz, Noémie Sève, et al.
Eurosurveillance (2024) Vol. 29, Iss. 13
Open Access | Times Cited: 6
The effect of COVID-19 vaccine to the Omicron variant in children and adolescents: a systematic review and meta-analysis
Wenting Lu, Shuai Zeng, Yuan Yao, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 6
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023–January 2024
Charlotte Lanièce Delaunay, Aryse Martins Melo, Marine Maurel, et al.
Vaccine (2024) Vol. 42, Iss. 19, pp. 3931-3937
Open Access | Times Cited: 6
COVSIM: A stochastic agent-based COVID-19 SIMulation model for North Carolina
Erik Rosenstrom, Julie S. Ivy, María E. Mayorga, et al.
Epidemics (2024) Vol. 46, pp. 100752-100752
Open Access | Times Cited: 5
Proactive vs. reactive COVID-19 screening in schools: lessons from experimental protocols in France during the Delta and Omicron waves
Elisabetta Colosi, Bruno Lina, Christelle Elias, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Early COVID-19 and protection from Omicron in a highly vaccinated population in Ontario, Canada: a matched prospective cohort study
Altynay Shigayeva, Christopher Kandel, Lubna Farooqi, et al.
BMC Infectious Diseases (2025) Vol. 25, Iss. 1
Open Access
Changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States between December 2021 and November 2022
Fayette Klaassen, Melanie H. Chitwood, Ted Cohen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 22
Increased vaccine sensitivity of an emerging SARS-CoV-2 variant
Joseph A. Lewnard, Vennis Hong, Jeniffer S. Kim, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce
Zachary Willis, Carlos R. Oliveira, Mark J. Abzug, et al.
Journal of the Pediatric Infectious Diseases Society (2024) Vol. 13, Iss. 3, pp. 159-185
Open Access | Times Cited: 4
Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico
José Antonio Montes-González, Christian Arturo Zaragoza-Jiménez, Neftalí Eduardo Antonio-Villa, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 10
SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses
Olha Puhach, Mathilde Bellon, Kenneth Adea, et al.
EBioMedicine (2023) Vol. 98, pp. 104893-104893
Open Access | Times Cited: 10
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial
Avika Dixit, Richard L. Bennett, Kashif Ali, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 7, pp. 687-697
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top